LncRNA HOXA‑AS2 promotes the progression of epithelial ovarian cancer via the regulation of miR‑372
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Homeobox A cluster antisense RNA2 (HOXA-AS2) promotes epithelial ovarian cancer (EOC) progression by upregulating miR-372. Targeting HOXA-AS2 may offer a new therapeutic strategy for EOC patients.
Area Of Science
- Molecular oncology
- RNA biology
Background
- Long non-coding RNAs (lncRNAs) play roles in cancer development.
- The specific function of HOXA-AS2 in epithelial ovarian cancer (EOC) is not well understood.
Purpose Of The Study
- To investigate the role of HOXA-AS2 in EOC progression.
- To explore the underlying molecular mechanism involving microRNA regulation.
Main Methods
- Quantitative real-time PCR to assess HOXA-AS2 expression.
- Cell proliferation, migration, invasion, and apoptosis assays.
- Bioinformatic analysis (ENCORI database) and molecular assays (RNA pull-down, luciferase reporter assays) to identify and validate miRNA interactions.
Main Results
- HOXA-AS2 expression is upregulated in EOC tissues and correlates with advanced grade and poor prognosis.
- Knockdown of HOXA-AS2 inhibits EOC cell proliferation, invasion, and migration, while promoting apoptosis.
- HOXA-AS2 acts as a competing endogenous RNA (ceRNA) to regulate miR-372, and miR-372 downregulation reverses the effects of HOXA-AS2 knockdown.
Conclusions
- HOXA-AS2 promotes EOC progression via the ceRNA mechanism targeting miR-372.
- HOXA-AS2 represents a potential therapeutic target for epithelial ovarian cancer.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...